<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01239888</url>
  </required_header>
  <id_info>
    <org_study_id>MAPRC 2010CK</org_study_id>
    <nct_id>NCT01239888</nct_id>
  </id_info>
  <brief_title>Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression - A Pilot Study</brief_title>
  <official_title>Phase IB Study of Efficacy and Safety of Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Alfred</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Alfred</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether an oxytocin ad-on, or oxytocin and tibolone&#xD;
      ad-on can induce a response to antidepressants in patients with treatment resistant&#xD;
      depression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We are examining the efficacy and safety of oxytocin or oxytocin and tibolone with an&#xD;
      antidepressant (SSRIs) in treatment resistant depression in a double-blind randomized&#xD;
      clinical trial.&#xD;
&#xD;
      A secondary objective is the evaluation of neurobiological factors contributing to drug&#xD;
      efficacy in treatment resistant depression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Assessed at different time points: 1 week, 2 weeks, 4 weeks, 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Hamilton Rating Scale for Depression (HAM-D)</measure>
    <time_frame>Assessed at different time points: 1 week, 2 weeks, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Beck Depression Inventory II (BDI-II)</measure>
    <time_frame>Assessed at different time points: 1 week, 2 weeks, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in State Trait Anxiety Inventory (STAI)</measure>
    <time_frame>Assessed at different time points: 1 week, 2 weeks, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Symptom Check List</measure>
    <time_frame>baseline, week 2, week 4, week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived stress scale</measure>
    <time_frame>baseline, week 2, week 4, week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh sleep quality index</measure>
    <time_frame>baseline, week 2, week 4, week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)</measure>
    <time_frame>baseline, week 2, week 4, week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxytocin and Tibolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>20 IU of intranasal oxytocin twice per day for 8 weeks, and a placebo (oral) for the 8 week trial</description>
    <arm_group_label>Oxytocin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin and Tibolone</intervention_name>
    <description>20 IU of intranasal oxytocin twice per day for 8 weeks, and 2.5mg oral tibolone for the 8 week trial</description>
    <arm_group_label>Oxytocin and Tibolone</arm_group_label>
    <other_name>Livial (tibolone)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>20 IU of intranasal placebo twice per day for 8 weeks, and a placebo (oral) for the 8 week trial</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women&#xD;
&#xD;
          -  18-45 years&#xD;
&#xD;
          -  Current DSM-IV diagnosis of Major Depression&#xD;
&#xD;
          -  Comorbid anxiety disorders secondary to depression will be included&#xD;
&#xD;
          -  Past history of at least 2 failed treatment responses (including SSRIs) at the highest&#xD;
             tolerated dose for at least 4-6 weeks&#xD;
&#xD;
          -  A MADRS score &gt;20 at randomization&#xD;
&#xD;
          -  Women on a stable dose of an SSRI (sertraline, citalopram, escitalopram, paroxetine,&#xD;
             fluoxetine or fluvoxamine) for at least 4-6 weeks.&#xD;
&#xD;
          -  A negative pregnancy test at screening&#xD;
&#xD;
          -  A clinically acceptable Pap smear within the past 2 years&#xD;
&#xD;
          -  Must be able to use intranasal spray and swallow tablets&#xD;
&#xD;
        Patients may take up to 2 sleep medications permitted at a dose considered reasonable by&#xD;
        the investigating team. Limited adjustments in sleep medication are acceptable. Patients&#xD;
        will be asked to notify the researchers of any changes to their sleep medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any previous history of adverse side-effects to escitalopram (or other SSRI)&#xD;
&#xD;
          -  Use of oral contraceptives (or any hormonal method of contraception) for the duration&#xD;
             of the study&#xD;
&#xD;
          -  DSM-IV defined substance dependence, history of bipolar disorder, schizoaffective&#xD;
             disorder or schizophrenia&#xD;
&#xD;
          -  Significant unstable medical illness including epilepsy, diabetes or cardiac related,&#xD;
             renal or liver disease, hormone dependent cancer or pregnancy&#xD;
&#xD;
          -  A BMI&lt;18 or &gt; 34kg/m2&#xD;
&#xD;
          -  Planning for pregnancy&#xD;
&#xD;
          -  Renal disease, history of cerebrovascular disease, thrombo-embolic disorders,&#xD;
             myocardial infarction or angina at any time before study entry or thrombo-phlebitis&#xD;
             within the last 5 years, or any other major illness that has occurred within the last&#xD;
             6 months.&#xD;
&#xD;
          -  An undiagnosed genital bleeding&#xD;
&#xD;
          -  Moderate to severe acne or hirsutism, have used antiandrogen therapy for acne or&#xD;
             hirsutism in the preceding 5 years, have androgenic alopecia ( will exclude women with&#xD;
             clinically meaningful androgen excess)&#xD;
&#xD;
          -  Active malignancy, or treatment for malignancy in the preceding 6 months (excluding&#xD;
             non-melanotic skin cancer)&#xD;
&#xD;
          -  Alcohol consumption in excess of 3 standard drinks per day&#xD;
&#xD;
          -  Lactose intolerance&#xD;
&#xD;
          -  An abnormal thyroid stimulating hormone (TSH) value at screening confirmed by a Free&#xD;
             T4 outside the normal laboratory range (patients with an abnormal TSH, normal Free T4&#xD;
             and no clinical signs or symptoms of thyroid disease, with or without replacement&#xD;
             treatment, may be admitted to the study).&#xD;
&#xD;
          -  A history of allergic reactions to androgens (oral or patch)&#xD;
&#xD;
          -  Chronic medications: aspirin and warfarin&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Keating, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monash University and the Alfred</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlotte Keating, PhD</last_name>
    <phone>+61 3 9076 5180</phone>
    <phone_ext>5180</phone_ext>
    <email>charlotte.keating@monash.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Monash Alfred Psychiatry Research Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Keating, PhD</last_name>
      <email>charlotte.keating@monash.edu</email>
    </contact>
    <investigator>
      <last_name>Charlotte Keating, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Fitzgerald, MBBS, MPM, FRANZCP, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jayashri Kulkarni, MBBS, MPM, FRANZCP, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alan Tilbrook, BAgSc(Hons), PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony DeCastella, DipAppSci, BA, MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>November 9, 2010</study_first_submitted>
  <study_first_submitted_qc>November 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2010</study_first_posted>
  <last_update_submitted>January 15, 2012</last_update_submitted>
  <last_update_submitted_qc>January 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Alfred</investigator_affiliation>
    <investigator_full_name>Charlotte Keating</investigator_full_name>
    <investigator_title>Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Treatment resistant depression</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>Estrogen Modulators</keyword>
  <keyword>HPA axis</keyword>
  <keyword>Mental Disorders</keyword>
  <keyword>Estrogens</keyword>
  <keyword>Tibolone</keyword>
  <keyword>Estrogen Receptor Modulators</keyword>
  <keyword>Androgens</keyword>
  <keyword>Hormones</keyword>
  <keyword>Hormone Substitutes</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Hormone Antagonists</keyword>
  <keyword>Bone Density Conservation Agents</keyword>
  <keyword>Estrogen Antagonists</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tibolone</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

